PIB: Pharmaceutical industry in Maharashtra
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
Biopharma and CROs to benefit from simplified access to global research sites
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Merck’s first microbiology application and training lab in India
Subscribe To Our Newsletter & Stay Updated